That’s how MedImmune and a collection of regional stakeholders say Greater Washington should brand itself to better promote its biotech and life sciences industry. The name was introduced as part of the BioHealth Capital Region forum at MedImmune headquarters in Gaithersburg.
Everyone knows what Silicon Valley and Research Triangle Park are.
What about the BioHealth Capital Region?
With one of the largest, most robust pipelines in the industry — including more than 120 research projects and product candidates, we are focused on three core therapeutic areas: Oncology; Respiratory, Inflammation and Autoimmune; and Cardiovascular and Metabolic Disease. But, we also are opportunity-driven in Infectious Disease.
BioHealth Innovation is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. It is a private-public partnership in the form of a 501 (c)(3) nonprofit that connects the Region’s innovation assets to provide integrated technical knowledge, financial means and entrepreneurial/managerial expertise to turn promise into prosperity for the region while advancing human health.
BHI will accomplish its mission by building an entrepreneurial ecosystem, working directly with federal and academic technology transfer offices, making various types of risk capital readily available to promising biohealth startups, strengthening and connecting the local supply of industry talent, developing a regional brand and reputation, and advocating for improved business and regulatory conditions in the industry.